Skip to main
MBIO
MBIO logo

Mustang Bio (MBIO) Stock Forecast & Price Target

Mustang Bio (MBIO) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mustang Bio Inc. is leveraging its expertise in CAR T therapies, which have shown promise in treating various cancers and autoimmune conditions, providing a strong foundation for future growth. The company's strategic focus on MB-106, particularly its potential in autoimmune indications, highlights an untapped market with significant upside potential that could enhance the company's overall valuation. Furthermore, the encouraging data from heavily pre-treated patient populations not only reinforces the therapeutic efficacy of their treatments but also positions Mustang Bio favorably within the competitive landscape of biopharmaceutical innovation.

Bears say

The analysis suggests a negative outlook for Mustang Bio due to potential roadblocks in their clinical trials and difficulties in securing sufficient funding for drug development, which could impact the company's ability to progress its pipeline. Additionally, a significant reduction in the price target reflects adjustments for an increased fully diluted share count following recent equity and warrant raises, as well as a higher discount rate applied due to anticipated financing challenges. These factors cumulatively indicate increased financial risks and uncertainties that could hinder the company's growth prospects and shareholder value.

Mustang Bio (MBIO) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mustang Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mustang Bio (MBIO) Forecast

Analysts have given Mustang Bio (MBIO) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Mustang Bio (MBIO) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mustang Bio (MBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.